Description
CardioAktiv Taurine Pharmacodynamics
Taurine is a natural product of the metabolism of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, a positive effect on the phospholipid composition of cell membranes, normalizes the exchange of calcium and potassium ions in cells. Taurine has been shown to be an inhibitory neurotransmitter, it has an anti-stressor effect, can regulate the release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones, as well as regulate responses to them. Participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; it affects enzymes such as cytochromes involved in the metabolism of various xenobacteria.
Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver disease taurine increases blood flow and reduces the severity of cytolysis.
Treatment with CardioAktiv ®
Taurine during cardiovascular failure (CVF) leads to the reduction of congestion in the small and large circulatory system: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum contraction and relaxation rate, contractility and relaxation indices). The drug moderately reduces blood pressure (BP) in patients with arterial hypertension and has almost no effect on BP in patients with cardiovascular insufficiency with reduced BP.
CardioAktiv ® Taurine reduces side effects from overdose of cardiac glycosides and slow calcium channel blockers, reduces hepatotoxicity of antifungal drugs. Improves performance under heavy physical exertion.
For diabetes mellitus, approximately 2 weeks after the start of treatment with CardioActiv® Taurine blood glucose concentration is decreased. There is also a significant decrease in triglyceride concentration, to a lesser extent, cholesterol concentration, reduction of plasma atherogenicity of lipids. Long-term use of the drug (about 6 months) showed improvement in the microcirculatory blood flow in the eye. Taurine improves metabolic processes in the heart, liver and other organs and tissues.
In chronic diffuse liver diseases taurine increases blood flow and reduces the severity of cytolysis.
Indications
– Diabetes mellitus type 2, including with moderate hypercholesterolemia;
– Diabetes mellitus type 1;
– Cardiovascular insufficiency of various etiologies;
– intoxication caused by cardiac glycosides;
– As a hepatoprotector in patients receiving antifungal agents.
Contraindications .
Hypersensitivity to the drug. Age under 18 years old due to insufficient data on efficacy and safety.
Consult your doctor before taking this medicine if you suffer from one of the above mentioned conditions.
Dosage and administration
- The drug is taken orally, 20 minutes before a meal.
- In diabetes mellitus type 2, including moderate hypercholesterolemia: 500 mg (1 tablet) 2 times a day in monotherapy or in combination with other hypoglycemic agents for oral administration, the course duration – as recommended by the physician.
- In diabetes mellitus type 1: 500 mg (1 tablet) 2 times a day in combination with insulin therapy for 3-6 months.
- In cardiovascular failure: 250-500 mg (1/2 – 1 tablet) 2 times a day, the treatment course is 30 days.
- The dose can be increased to 2 – 3 g (4-6 tablets) a day.
- When intoxication by cardiac glycosides: at least 750 mg (1.5 tablets) a day.
- As a hepatoprotector: 500 mg (1 tablet) 2 times a day during the whole course of taking antifungal drugs.
